ArticleBiochemical genetics2026
Kallikrein-Related Peptidase 4 Inhibits Laryngeal Squamous Cell Carcinoma Potentially via Involvement of the Wnt/β-Catenin Signaling Pathway.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant tumors of the head and neck with an increasing incidence worldwide. As a secreted serine protease, Kallikrein-related peptidase 4 (KLK4) has been reported to exert divergent tumor-modulating roles across multiple malignancies: it acts as a tumor suppressor in some cancers while promoting progression in others. However, its role in LSCC remains unclear. The aberrant activation of Wnt/β-catenin signaling is closely linked to tumor progression in most malignancies, hence we focused on this pathway to explore the downstream mechanism of KLK4. The expression of KLK4 was analyzed in clinical samples and LSCC cell lines using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. AMC-HN-8 cells were transfected with KLK4 plasmids, and the effects on proliferation, apoptosis, and epithelial-mesenchymal transition (EMT) were assessed using EDU assays, flow cytometry, and western blotting. The regulatory role of KLK4 on the Wnt/β-catenin signaling pathway was further investigated by treating cells with the Wnt/β-catenin agonist SKL2001. KLK4 expression was significantly downregulated in LSCC clinical samples and cell lines. KLK4 overexpression in LSCC cells inhibited cell proliferation, promoted apoptosis, and reversed the abnormal expression of EMT-related molecular markers. Moreover, KLK4 overexpression modulated the Wnt/β-catenin signaling by downregulating Wnt3a, β-catenin, and downstream targets. Treatment with SKL2001 reversed these effects by restoring cell proliferation, reducing apoptosis, and promoting EMT. KLK4 modulates LSCC cell proliferation, apoptosis and the expression of EMT-related markers, which are associated with the activity of the Wnt/β-catenin signaling pathway.
Indexed as
Identifiers
42623006What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.